Rituximab chimeric anti‐CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura

@article{Brndstrup2005RituximabCA,
  title={Rituximab chimeric anti‐CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura},
  author={Peter Br{\ae}ndstrup and Ole Weis Bjerrum and Ove Juul Nielsen and Bjarne Anker Jensen and Nielsaage T{\o}ffner Clausen and Per Boye Hansen and Ivan Andersen and Kai Gjerl{\o}ff Schmidt and Torben M. Andersen and Niels Anker Peterslund and Henrik Sverre Birgens and Torben Plesner and Bjarne Bach Pedersen and Hans Carl Hasselbalch},
  journal={American Journal of Hematology},
  year={2005},
  volume={78}
}
Idiopathic thrombocytopenic purpura is an autoimmune disease which involves opsonization of platelets by autoantibodies directed against different surface glycoproteins, leading to their premature destruction by the reticuloendothelial system. Management of patients with refractory ITP is difficult. Recent studies have shown that rituximab, a chimeric anti‐CD20 monoclonal antibody, is useful in the treatment of these patients, with overall response rates of about 50%. Most published reports… 
Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab
TLDR
The data confirm that rituximab is well tolerated and effective in refractory and relapsed immune thrombocytopenias; however, response duration was short, and only about one fifth of the authors' patients enjoyed a long-lasting remission.
Successful Treatment of Refractory Idiopathic Thrombocytopenic Purpura and Neutropenia with the Monoclonal Antibody, Rituximab
TLDR
A 22-year-old male with idiopathic autoimmune thrombocytopenia whose diagnosis was made at age of eight is described and his response improvement persisted during follow up for 9 months, indicating that B-cells may play a central role in the pathogenesis of ITN.
Can rituximab replace splenectomy in immune thrombocytopenic purpura?
  • V. Dabak, A. Hanbali, P. Kuriakose
  • Medicine
    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • 2009
TLDR
This study shows higher CR, comparable overall response rates, but with a longer duration of response when compared to the published literature, mainly as a second line treatment regimen prior to splenectomy.
Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
Rituximab in autoimmune pancytopenia: a case report and review of literature
TLDR
A case of autoimmune pancytopenia successfully treated with rituximab is presented and a direct antiglobulin test revealed a monospecific anti-IgG and the eluate was reactive with all reagent red cells, consistent with an AIHA.
The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura
TLDR
It is shown that the anti-CD20 antibody, rituximab, induces a clinically significant response in severe chronic ITP patients, who are unresponsive to other therapeutic options.
Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura
TLDR
The evidence to support the use of rituximab in ITP is uncertain and a systematic review of the literature was performed to evaluate the efficacy and safety of this treatment.
Rituximab treatment for symptomatic chronic ITP
TLDR
It is concluded that rituximab should be given to those symptomatic ITP patients who would otherwise be referred for splenectomy; only those who fail ritUXimab treatment should proceed to surgery.
A modified regimen of rituximab in pemphigus: A retrospective study
TLDR
It is concluded that rituximab is still very effective at half the dose in the conventional RA protocol, and although it is a highly efficacious drug, it must be used with great caution, keeping in mind, these catastrophic side effects.
Rituximab in Previously Treated Primary Immune Thrombocytopenia Patients: Evaluation of Short- and Long-Term Efficacy and Safety
TLDR
These data confirm, over a long period of observation, the efficacy and safety of rituximab treatment in the management of patients with resistant pITP.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 54 REFERENCES
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
TLDR
Rituximab therapy has a limited but valuable effect in patients with chronic ITP, and in view of its mild toxicity and the lack of effective alternative treatments, its use in the setting of chronic refractory ITP is warranted.
Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.
TLDR
The cases of 3 patients with refractory ITP who achieved acceptable platelet counts after treatment with rituximab are reported.
Refractory autoimmune thrombocytopenic purpura: Responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab)
TLDR
The results support the use of this product, rituximab, in the treatment of patients with autoimmune thrombocytopenia who have not attained a hemostatically effective platelet count following splenectomy and require a continuing therapeutic management program.
Treatment of relapsed idiopathic thrombocytopenic purpura with the anti‐CD20 monoclonal antibody rituximab: a pilot study
Abstract: We performed a prospective pilot study on 12 patients to evaluate the efficacy of the anti‐CD20 monoclonal antibody rituximab in relapsed idiopathic thrombocytopenic purpura (ITP).
Therapy for Adults with Refractory Chronic Immune Thrombocytopenic Purpura
Adult chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder caused by one or more antiplatelet autoantibodies usually directed to the platelet glycoprotein IIb/IIIa complex, GPIb/IX
Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
TLDR
It is suggested that rituximab deserves early consideration as salvage therapy for immune cytopenias that are refractory to both corticosteroid treatment and splenectomy.
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
TLDR
Rituximab appeared to be active and safe in some patients with refractory autoimmune hemolytic anemia and thrombocytopenia, and data from literature suggest that this agent may have a therapeutic role in autoimmune diseases.
Overview of idiopathic thrombocytopenic purpura: new approach to refractory patients.
  • J. Bussel
  • Medicine, Biology
    Seminars in oncology
  • 2000
TLDR
Idiopathic thrombocytopenic purpura is a disorder in which autoantibodies are made to platelets, resulting in accelerated platelet destruction, and patients with multiple medical conditions and medications should be individualized.
A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.
TLDR
A prospective pilot phase I/II clinical trial to evaluate the toxicity and response rate of the chimeric anti-CD20 monoclonal antibody, rituximab (Rituxan), in the treatment of patients with immune thrombocytopenic purpura, finding three of nine patients who have received ritUXimab at doses close to the full dose have shown an objective clinical response.
B-cell compartment as the selective target for the treatment of immune thrombocytopenias.
TLDR
Rituximab appears to be a promising immunotherapeutic agent for the treatment of autoimmune thrombocytopenias with well tolerated treatment and no acute or delayed toxic events were recorded.
...
1
2
3
4
5
...